Tempus AI has launched a new program aimed at using algorithms to detect potentially actionable biomarkers in patients for further testing. The program is part of the larger Tempus Next platform and is initially targeting human epidermal growth factor receptor 2 (HER2) testing in certain metastatic cancer patients. The new Next program, now available on Tempus' platform, will initially be focused on the identification of care gaps associated with human epidermal growth factor receptor 2 (HER2) testing in select metastatic cancer patients.

The key component of the Next launch is a novel algorithm that works as a part of Tempus' xR, an RNA sequencing assay, targeting patients who could potentially benefit from on-guideline immunohistochemistry (IHC) testing. The algorithm uses RNA data to anticipate  IHC/ISH positivity in a tumor sample, subsequently signaling physicians about the patients who are likely to test positive for HER2 for potential further testing. This program is currently being piloted at specific sites. The company has self-funded the algorithm's development along with partner support from life sciences firms.